Phenotyping of peripheral blood mononuclear cells of patients with advanced heavily pre-treated adenocarcinoma of the stomach and gastro-esophageal junction

详细信息    查看全文

• 作者：Marie-Cristine Kuehnle (1)
  Sebastian Attig (2) (3)
  Cedrik M. Britten (2) (4)
  Henning Schulze-Bergkamen (5)
  Florian Lordick (6)
  Goetz von Wichert (7)
  Peter Thuss-Patience (8)
  Alexander Stein (10) (9)
  Martin Schuler (11) (12)
  Florian Bassermann (13)
  Ugur Sahin (2) (4)
  ?zlem Türeci (1)
  
• 关键词：Gastric adenocarcinoma ; Immune phenotyping ; Anti ; tumor immune response ; Immunomonitoring
• 刊名：Cancer Immunology, Immunotherapy
• 出版年：2014
• 出版时间：December 2014
• 年：2014
• 卷：63
• 期：12
• 页码：1273-1284
• 全文大小：531 KB
• 参考文献：1. Kantoff PW, Higano CS, Shore ND et al (2010) Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 363:411-22. doi:10.1056/NEJMoa1001294 CrossRef
  2. Fong L, Small EJ (2008) Anti-cytotoxic T-lymphocyte antigen-4 antibody: the first in an emerging class of immunomodulatory antibodies for cancer treatment. J Clin Oncol 26:5275-283. doi:10.1200/JCO.2008.17.8954 CrossRef
  3. Weber JS, Hamid O, Chasalow SD et al (2012) Ipilimumab increases activated T cells and enhances humoral immunity in patients with advanced melanoma. J Immunother 35:89-7. doi:10.1097/CJI.0b013e31823aa41c CrossRef
  4. Brahmer JR, Tykodi SS, Chow LQ et al (2012) Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 366:2455-465. doi:10.1056/NEJMoa1200694 CrossRef
  5. Arnould L, Gelly M, Penault-Llorca F et al (2006) Trastuzumab-based treatment of HER2-positive breast cancer: an antibody-dependent cellular cytotoxicity mechanism? Br J Cancer 94:259-67. doi:10.1038/sj.bjc.6602930 CrossRef
  6. Kurai J, Chikumi H, Hashimoto K et al (2007) Antibody-dependent cellular cytotoxicity mediated by cetuximab against lung cancer cell lines. Clin Cancer Res 13:1552-561. doi:10.1158/1078-0432.CCR-06-1726 CrossRef
  7. Bibeau F, Lopez-Crapez E, Di Fiore F et al (2009) Impact of Fc{gamma}RIIa-Fc{gamma}RIIIa polymorphisms and KRAS mutations on the clinical outcome of patients with metastatic colorectal cancer treated with cetuximab plus irinotecan. J Clin Oncol 27:1122-129. doi:10.1200/JCO.2008.18.0463 CrossRef
  8. Cartron G, Dacheux L, Salles G et al (2002) Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood 99:754-58 CrossRef
  9. Musolino A, Naldi N, Bortesi B et al (2008) Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer. J Clin Oncol 26:1789-796. doi:10.1200/JCO.2007.14.8957 CrossRef
  10. Racila E, Link BK, Weng WK et al (2008) A polymorphism in the complement component C1qA correlates with prolonged response following rituximab therapy of follicular lymphoma. Clin Cancer Res 14:6697-703. doi:10.1158/1078-0432.CCR-08-0745 CrossRef
  11. Braun DP, Harris JE (1981) Relationship of leukocyte numbers, immunoregulatory cell function, and phytohemagglutinin responsiveness in cancer patients. J Natl Cancer Inst 67:809-14
  12. Hong WS, Kim CM, Lee JO, Kang TW, Yun TK, Kim CY (1990) Natural killer and lymphokine-activated killer activities in stomach cancer patients with special emphasis on the effect of 5-fluorouracil, adriamycin and mitomycin-C chemotherapy. Jpn J Clin Oncol 20:87-3
  13. Hong WS, Min YI, Son YS, Hong SI (1995) Peripheral blood lymphocyte subsets in patients with stomach cancer. J Korean Med Sci 10:164-68 CrossRef
  14. Dillman RO, Koziol JA, Zavanelli MI et al (1984) Immunoincompetence in cancer patients. Assessment by in vitro stimulation tests and quantification of lymphocyte subpopulations. Cancer 53:1484-491 CrossRef <
• 作者单位：Marie-Cristine Kuehnle (1)
  Sebastian Attig (2) (3)
  Cedrik M. Britten (2) (4)
  Henning Schulze-Bergkamen (5)
  Florian Lordick (6)
  Goetz von Wichert (7)
  Peter Thuss-Patience (8)
  Alexander Stein (10) (9)
  Martin Schuler (11) (12)
  Florian Bassermann (13)
  Ugur Sahin (2) (4)
  ?zlem Türeci (1)
  
  1. Ganymed Pharmaceuticals AG, An der Goldgrube 12, 55131, Mainz, Germany
  2. Translational Oncology (TRON), University Medical Center, Johannes Gutenberg University Mainz, Mainz, Germany
  3. Experimental and Translational Oncology, University Medical Center, Johannes Gutenberg University Mainz, Mainz, Germany
  4. Biontech RNA Pharmaceuticals GmbH, Mainz, Germany
  5. National Center for Tumor Diseases (NCT), Heidelberg University Hospital, Heidelberg, Germany
  6. University Cancer Center Leipzig (UCCL), University Clinic Leipzig, Leipzig, Germany
  7. Department of Internal Medicine, Sch?n Klinik Hamburg Eilbek, Hamburg, Germany
  8. Department of Haematology, Oncology and Tumorimmunology, Campus Virchow-Klinikum, Charité - University Medicine Berlin, Berlin, Germany
  10. Department of Oncology, Hematology, BMT with Section Pneumology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
  9. Hubertus Wald Tumour Center, University Cancer Center Hamburg, Hamburg, Germany
  11. Department of Medical Oncology, West German Cancer Center, University Duisburg-Essen, Essen, Germany
  12. German Cancer Consortium (DKTK), Heidelberg, Germany
  13. Department of Medicine III, Klinikum rechts der Isar, Technische Universit?t München, Munich, Germany
  
• ISSN：1432-0851

文摘

Immunotherapeutic approaches are emerging as promising new treatment options for patients with solid cancers. The host immune system in cancer patients is dysfunctional due to a number of reasons. The level of immunosuppression is variable at the time of diagnosis and depends on the particular cancer entity, stage, and prior anti-cancer therapies. For many cancer entities, the immune alterations of the respective patient population have not been further characterized even though a patient’s immunophenotype may be prognostic for the course of the disease or predictive for clinical/biological response to immunotherapy. In this study, we used flow cytometry to determine the phenotype of peripheral blood mononuclear cells (PBMCs) from 30 patients with heavily pre-treated, advanced adenocarcinoma of the stomach and gastro-esophageal junction. The frequencies and activation status of relevant immune effector populations were determined in PBMCs and compared to those of healthy individuals. This report provides comprehensive immune phenotyping data of a patient population with a high medical need.